| 摘要: |
| [摘要]目的:观察布地奈德联合复方异丙托溴铵雾化吸入治疗毛细支气管炎的疗效,探讨不同疗程吸入布地奈德对毛细支气管炎预后的影响。方法:选择 2010年9月至2013年8月住院治疗确诊为毛细支气管炎的112例患儿,随机分为三组。在综合治疗基础上,治疗1组给予布地奈德混悬液联合复方异丙托溴铵雾化吸入治疗7d,缓解期继续给予布地奈德气雾剂雾化吸入治疗至3个月;治疗2组给予布地奈德混悬液联合沙丁胺醇溶液雾化吸入治疗7d;对照组单用沙丁胺醇溶液雾化吸入治疗7d。观察三组患儿临床症状消失时间、住院时间,比较三组患儿疗效,并随访观察停药后1年喘息性疾病患病例数及患病率。结果:
治疗组症状消失时间、住院时间均短于对照组(P<0郾 05),且治疗1组较治疗2组更短(P<0.05)。治疗1组显效率高于治疗2组及对照组(P<0.01)。治疗1组停药1年喘息性疾病患病率(25.0%) 低于较治疗2组(48.5%) 和对照组(51.4%),差异有统计学意义(P<0.05),而治疗2组与对照组比较差异无统计学意义(P>0.05)。 结论:布地奈德联合复方异丙托溴铵雾化吸入对缓解毛细支气管炎患儿急性期症状疗效肯定,毛细支气管炎缓解期早期给予布地奈德气雾剂吸入3个月,可降低喘息性疾病的发病率。 |
| 关键词: 布地奈德 复方异丙托溴铵 毛细支气管炎 预后 |
| DOI：doi:10.13407/j.cnki.jpp.1672-108X.2018.02.010 |
|
| 基金项目: |
|
| Atomize Inhaling Budesonide Combined with Compound Ipratropium Bromide on Bronchiolitis |
| Wang Yongfang, Wang Aiping, Wang Xuan, Xu Yufang |
| (The First People's Hospital of Zhengzhou, Henan Zhengzhou 450004, China) |
| Abstract: |
| [Abstract] Objective: To observe the therapeutic effect of atomize inhaling budesonide and compound ipratropium bromide in
bronchiolitis and explore the prognostic influence of budesonide. Methods: One hundred and twelve children with bronchiolitis were
divided into 3 groups randomly. The children in group 1 were treated 7 days with budesonide and compound ipratropium bromide, and
continued to therapy with budesonide 3 months, the children in group 2 were treated 7 days with budesonide and salbutamol, and the
control group was treated 7 days with salbutamol only. The disappearance time of the symptoms and the hospital stay were observed and therapeutic effects in 3 groups were evaluated. And the number and rate of asthmatic disease was followed up 1 year after discontinuation of the treatment. Results: The disappearance time of the symptoms and the hospital stay in treatment group were shorter than those in the control group (P<0.05), and the group 1 was shorter than group 2. The effect rate of the group1 was higher than group 2 and the control group(P<0.01), and the group 1 was higher than group 2 (P<0.05). With 1 year treatment in asthmatic disease, the prevalence rate in treatment group 1 (25.0%) was lower than group 2 (48.5%) and control group (51.4%)(P<0.05), but there was no statistical significance in group 2 and the control group (P>0.05). Conclusion: The therapeutic effect of atomize inhaling budesonide and compound ipratropium bromide to reduce the acute symptoms of children with bronchiolitis is sure. It
can reduce the risk to develop asthmatic disease with inhaled budesonide as an early intervention. |
| Key words: budesonide compound ipratropium bromide bronchiolitis prognostics |
